News Breaks |
|
|
| October 10, 2012 |
| 05:57 EDT |  | BSX | Boston Scientific: first patient enrolled in REPRISE II TAVR clinical trial
Boston Scientific has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease. This international, multi-center study includes 15 sites in Australia, France, Germany and the U.K.. The Lotus Valve System is the first transcatheter aortic valve replacement, or TAVR, device of its kind that is designed to minimize aortic regurgitation (leaking). The device is both fully repositionable and retrievable prior to release, offering predictable and precise placement. The results of the REPRISE II trial are expected to be used to support CE mark and other international regulatory approvals. Study enrollment is expected to be completed in the 1H of 2013. |
|
|
News For BSX From The Last 14 Days Check below for free stories on BSX the last two weeks. |
|
|
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT |  | BSX | I/O Central to host a conference
 Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| May 10, 2013 |
| 10:00 EDT |  | BSX | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:03 EDT | | BSX | Boston Scientific receives CEO Mark approval for Rhythmia mapping system
Subscribe for More Information |
|
| 05:46 EDT | | BSX | Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information |
|
| May 9, 2013 |
| 12:04 EDT | | BSX | Boston Scientific says data show Watchman device superior to warfarin
Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. |
|
| 09:27 EDT | | BSX | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT | | BSX | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
| |
| May 6, 2013 |
| 08:06 EDT | | BSX | Boston Scientific completes first-in-human clinical trial of IntellaTip Mifi XP
Boston Scientific completed a first-in-human clinical trial utilizing the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the United States. This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital. Patients with type 1 atrial flutter may exhibit symptoms that include palpitations, shortness of breath, fatigue, lightheadedness and fainting. Catheter ablation, a procedure in which localized electrical energy is delivered into the heart tissue aimed at restoring the continuous normal rhythm, has become a first-line treatment approach for patients with recurrent type 1 atrial flutter and demonstrates more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy. |
|
|
|
|
|
